IL-33 has been linked to the resistance of melanoma and breast cancer cells to conventional pharmacotherapeutics [63], which might indicate the possibility of targeting the IL-33/ST2 axis as an immune antitumor adjuvant. Here, IL33 is linked to breast cancer.